{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hereditary+Cancer+Syndromes&page=3", "query": { "condition": "Hereditary Cancer Syndromes", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 1150, "total_pages": 115, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hereditary+Cancer+Syndromes&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hereditary+Cancer+Syndromes&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T10:35:25.617Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00060372", "title": "Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Childhood Myelodysplastic Syndromes", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Disseminated Neuroblastoma", "Malignant Neoplasm", "Ovarian Choriocarcinoma", "Ovarian Embryonal Carcinoma", "Ovarian Immature Teratoma", "Ovarian Mature Teratoma", "Ovarian Mixed Germ Cell Tumor", "Ovarian Monodermal and Highly Specialized Teratoma", "Ovarian Polyembryoma", "Ovarian Yolk Sac Tumor", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Neuroblastoma", "Recurrent Ovarian Epithelial Cancer", "Recurrent Ovarian Germ Cell Tumor", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage II Ovarian Epithelial Cancer", "Stage III Malignant Testicular Germ Cell Tumor", "Stage III Multiple Myeloma", "Stage III Ovarian Epithelial Cancer", "Stage IIIA Breast Cancer", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Stage IV Ovarian Epithelial Cancer", "Testicular Choriocarcinoma", "Testicular Choriocarcinoma and Embryonal Carcinoma", "Testicular Choriocarcinoma and Seminoma", "Testicular Choriocarcinoma and Teratoma", "Testicular Choriocarcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma", "Testicular Embryonal Carcinoma and Seminoma", "Testicular Embryonal Carcinoma and Teratoma", "Testicular Embryonal Carcinoma and Teratoma With Seminoma", "Testicular Embryonal Carcinoma and Yolk Sac Tumor", "Testicular Embryonal Carcinoma and Yolk Sac Tumor With Seminoma", "Testicular Teratoma", "Testicular Yolk Sac Tumor", "Testicular Yolk Sac Tumor and Teratoma", "Testicular Yolk Sac Tumor and Teratoma With Seminoma" ], "interventions": [ { "name": "ipilimumab", "type": "DRUG" }, { "name": "therapeutic allogeneic lymphocytes", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 21, "start_date": "2003-04", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-03-27", "last_synced_at": "2026-10-04T10:35:25.617Z", "location_count": 5, "location_summary": "La Jolla, California • Atlanta, Georgia • Boston, Massachusetts", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00060372" }, { "nct_id": "NCT02471339", "title": "Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Neurofibromatosis Type 1", "Plexiform Neurofibromas" ], "interventions": [ { "name": "Acceptance and Commitment Therapy (ACT)", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "16 Years to 59 Years" }, "enrollment_count": 66, "start_date": "2015-07-07", "completion_date": "2020-12-23", "has_results": true, "last_update_posted_date": "2022-06-14", "last_synced_at": "2026-10-04T10:35:25.617Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02471339" }, { "nct_id": "NCT00792766", "title": "Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Tuberous Sclerosis", "Angiolipoma" ], "interventions": [ { "name": "everolimus (RAD001)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 20, "start_date": "2008-12", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2013-09-18", "last_synced_at": "2026-10-04T10:35:25.617Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00792766" }, { "nct_id": "NCT04906382", "title": "Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Lynch Syndrome", "Recurrent Endometrial Carcinoma", "Recurrent Endometrial Clear Cell Adenocarcinoma", "Recurrent Uterine Corpus Carcinosarcoma", "Mismatch Repair Deficiency", "Recurrent Endometrial Cancer", "Metastatic Endometrial Cancer" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Tislelizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Floor Backes, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 2, "start_date": "2021-07-01", "completion_date": "2022-09-01", "has_results": false, "last_update_posted_date": "2025-02-13", "last_synced_at": "2026-10-04T10:35:25.617Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04906382" }, { "nct_id": "NCT04099966", "title": "AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukemia", "Severe Aplastic Anemia", "Non-hodgkin Lymphoma", "Hodgkin Lymphoma", "Kostmann", "Diamond Blackfan Anemia", "Amegakaryocytic Thrombocytopenia", "Sickle Cell Disease", "Beta-Thalassemia" ], "interventions": [ { "name": "alpha beta depletion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mitchell Cairo", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Day to 30 Years" }, "enrollment_count": 20, "start_date": "2021-04-01", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-08-08", "last_synced_at": "2026-10-04T10:35:25.617Z", "location_count": 1, "location_summary": "Valhalla, New York", "locations": [ { "city": "Valhalla", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04099966" }, { "nct_id": "NCT01362803", "title": "AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Neurofibromatosis 1", "Neurofibromatosis Type 1", "NF1", "Neurofibroma, Plexiform" ], "interventions": [ { "name": "AZD6244", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 99, "start_date": "2011-09-21", "completion_date": "2032-01-01", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-04T10:35:25.617Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Bethesda, Maryland • Cincinnati, Ohio + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01362803" }, { "nct_id": "NCT06735820", "title": "Early Phase Study Evaluating MEK and MDM2 Inhibition in Patients With NF1 and MPNST", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Malignant Peripheral Nerve Sheath Tumor (MPNST)", "Neurofibromatosis 1 (NF1)", "Atypical Neurofibroma" ], "interventions": [ { "name": "APG-115", "type": "DRUG" }, { "name": "Selumetinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AeRang Kim", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2026-06-01", "completion_date": "2028-10-01", "has_results": false, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-04T10:35:25.617Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Dallas, Texas", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06735820" }, { "nct_id": "NCT03081455", "title": "Impact of a Process Intervention on Screening and Testing Outcomes for Common Hereditary Cancer Syndromes", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hereditary Cancer" ], "interventions": [ { "name": "Diagnostic Test", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Myriad Genetic Laboratories, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 145, "start_date": "2017-02-13", "completion_date": "2017-08-04", "has_results": false, "last_update_posted_date": "2017-08-08", "last_synced_at": "2026-10-04T10:35:25.617Z", "location_count": 2, "location_summary": "Waterbury, Connecticut • Syracuse, New York", "locations": [ { "city": "Waterbury", "state": "Connecticut" }, { "city": "Syracuse", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03081455" }, { "nct_id": "NCT05377008", "title": "Intervention Effectiveness on the Neurocognitive Functioning of Children and Adolescents With Neurofibromatosis Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neurocognitive Deficit", "Mental Health Impairment", "Neurofibromatosis 1" ], "interventions": [ { "name": "OPTIMAL-SSI", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Virginia Commonwealth University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "6 Years to 16 Years" }, "enrollment_count": 38, "start_date": "2022-05-13", "completion_date": "2023-05-05", "has_results": false, "last_update_posted_date": "2023-09-22", "last_synced_at": "2026-10-04T10:35:25.617Z", "location_count": 1, "location_summary": "Richmond, Virginia", "locations": [ { "city": "Richmond", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05377008" }, { "nct_id": "NCT00379340", "title": "Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage III Kidney Wilms Tumor", "Stage IV Kidney Wilms Tumor" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Conventional Surgery", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dactinomycin", "type": "BIOLOGICAL" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Vincristine Sulfate Liposome", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "Children's Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "29 Years", "sex": "ALL", "summary": "Up to 29 Years" }, "enrollment_count": 395, "start_date": "2007-04-30", "completion_date": "2026-03-31", "has_results": true, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-04T10:35:25.617Z", "location_count": 199, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 143 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00379340" } ] }